about
Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out.Directly parameterized regression conditioning on being alive: analysis of longitudinal data truncated by deaths.For Health-Related Quality of Life and Other Longitudinal Data, Analysis Should Distinguish Between Truncation by Death and Data Missing Because of Nonresponse.Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast CancerLongitudinal Data with Follow-up Truncated by Death: Match the Analysis Method to Research AimsAssessment of joint and fascia manifestations in chronic graft-versus-host disease.DCE-MRI Background Parenchymal Enhancement Quantified from an Early versus Delayed Post-contrast Sequence: Association with Breast Cancer Presence.Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD ConsortiumMulticenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs.Education, cognitive function, and severity of neuropathology in Alzheimer disease.A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).Quantitative assessment of dynamic PET imaging data in cancer imaging.PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium.Improved diagnostic accuracy of breast MRI through combined apparent diffusion coefficients and dynamic contrast-enhanced kinetics.Design considerations for using PET as a response measure in single site and multicenter clinical trials.Validation of measurement scales in ocular graft-versus-host diseaseTumor-induced lymph node alterations detected by MRI lymphography using gadolinium nanoparticles.Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility RegionsParametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma.Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.Promise and pitfalls of quantitative imaging in oncology clinical trials.Effect of (18)F-FDG uptake time on lesion detectability in PET imaging of early stage breast cancerMulticenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Diffusion-Weighted Breast Magnetic Resonance Imaging: A Semiautomated Voxel Selection Technique Improves Interreader Reproducibility of Apparent Diffusion Coefficient Measurements.Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer.Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.Clinical indication and patient age predict likelihood of malignancy in suspicious breast MRI lesions.Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey.Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study.ATM protein is deficient in over 40% of lung adenocarcinomas.Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.Probability of malignancy for lesions detected on breast MRI: a predictive model incorporating BI-RADS imaging features and patient characteristics.Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
P50
Q30952576-12D51353-037C-4691-B2B7-5DF240E65322Q30984999-A95C9D13-8B5B-46FB-A5D7-E959CC888D98Q31127087-F8EED1BC-6D12-43C8-A5D1-3BAA226306E7Q33369337-D27B7182-5DAA-4773-96CA-B32715B43B9FQ33429434-5550A3B8-BB3A-47E9-911A-65992CED3A31Q33527926-9B20767D-241A-4FEA-87AC-17D028D544B5Q33583436-F2FBF479-6A65-4863-A52B-C722FEEC3580Q33704986-0AA7425C-6F36-4EDA-AE01-1CB2816AC51EQ33830644-E9072742-8060-420B-9CC7-CC49A8F3FBB9Q33921056-542D91E0-785D-486D-BE23-8F72EE6394B0Q34009105-1FA56349-BD77-486D-A327-53C9F0C0C858Q34213855-8C272761-7DAE-4FC9-8231-8A9D96A3D683Q34346931-C6ABCAAC-590D-44D6-A152-D9B58D83B405Q34914187-4992D2EA-0AD1-4007-85AC-403CDDEA02E6Q35007886-86354B8C-7448-46D9-B3A8-38350F96CE5AQ35009891-A530C65A-E743-4093-A305-4D24F95A9DC5Q35266002-CBD7C3B0-C82F-4FC4-B55E-986FF647F6D9Q35447075-042E4B4B-03BA-4F40-84B0-93926D88AEACQ35653277-8EB665AB-1D8E-446C-AFF7-58B8A03A3A76Q35803461-C9481524-FF6B-4051-A1D3-FAB2B5125EFBQ36205937-D51E19B6-904E-4A08-B58F-DD7248D42827Q36258075-0382333B-FB98-4A3F-A663-A47CF79BBBC0Q36279602-D16530F2-F8CF-4E41-BF3B-8EC03BFCD369Q36286840-06533B75-F943-4BE8-AA22-2BD3DB870F61Q36303765-DAD81B47-E784-4CAC-8D20-8A74142599FAQ36486024-BEC24245-5245-4134-9E3D-D7EE7D384D21Q36567875-0BDBB37B-4C33-46A7-85DD-3470FC853DE7Q36642923-56D6C9D1-0D96-4887-B8D1-C6A23CE35C26Q36921287-C39FAAFD-4007-47A9-997B-89D7F7DE8969Q37119479-2C807ACB-4633-4C65-BAE5-090F2EF81BB3Q37161785-828992CB-9C9D-404F-83B6-8A7A8F60B283Q37235591-7FD2FBF2-4021-40A3-AF4F-51A6C87E5394Q37332710-37EDB83D-8F20-4174-A61C-C3F2415BA1CBQ37592750-71A20544-7B30-4200-8893-4C58AB9EEE5AQ37603177-2B16610C-B987-426F-B9F2-7C1588680906Q37617192-96C132E8-ACBB-4175-8B01-2FF2559580E8Q37628924-CCEB7EF4-B687-44FC-8F0E-16EE3FFE2EAEQ37680499-87ECF108-D4F3-41A5-96E0-2B05A8CDA1A5Q37848173-2C31FD40-0DAC-4B45-90C3-71AE4194245DQ38086524-1C2BC25B-724A-4609-BE1D-409934B8619B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
B Kurland
@ast
B Kurland
@en
B Kurland
@es
B Kurland
@nl
type
label
B Kurland
@ast
B Kurland
@en
B Kurland
@es
B Kurland
@nl
prefLabel
B Kurland
@ast
B Kurland
@en
B Kurland
@es
B Kurland
@nl
P108
P106
P1153
6602766921
P31
P496
0000-0002-5669-0595